CervoMed Inc…announced today that it has completed enrollment in its Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia

neflamapimod (VX-745) - CervoMed

Jul 9, 2026